AMYRA is developing a unique enzyme combination for curative care of Celiac Disease and Non-Celiac Gluten Sensitivity (NCGS), which represent major public health issues. AMYRA’s products have the potential to establish the standard of care and majorly impact the lives of affected people.

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business